About Seer, Inc.
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Our novel Proteograph™ platform allows for the first-ever generation of proprietary proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, and affording comprehensive insights to deliver first-in-class liquid biopsy products with a goal of achieving very early disease detection.
We are advancing a portfolio of first-in-class liquid biopsy products to detect disease at early, pre-symptomatic stages to drive earlier treatment and improved outcomes. We will also seek to establish strategic collaborations with industry partners to leverage our Proteograph platform to impact drug discovery and development.